APELLIS PHARMACEUTICALS
Apellis Pharmaceuticals is an early-stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease. The company is leveraging courageous science, creativity, and compassion to deliver life-changing medicines. They aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. It was founded in 2008 and headquartered in Waltham, Massachusetts, United States.
APELLIS PHARMACEUTICALS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2008-01-01
Address:
Waltham, Massachusetts, United States
Country:
United States
Website Url:
http://www.apellis.com
Total Employee:
501+
Status:
Active
Contact:
502-241-4114
Total Funding:
643.53 M USD
Technology used in webpage:
Domain Not Resolving HSTS IPv6 ReCAPTCHA Organization Schema Person Schema Google ReCAPTCHA V2 JQuery CDN Microsoft
Similar Organizations
ANI Pharmaceuticals
ANI Pharmaceuticals manufactures oral solid dose products, as well as liquids and topicals.
Cabaletta Bio
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Circle Pharma
Circle Pharma is a provider of a macrocycle development platform intended to provide macrocyclic peptides.
Cytosorbents
Cytosorbents develops therapeutic devices used in purifying blood to treat life-threatening diseases.
Windtree Therapeutics
Windtree is a clinical-stage focused on developing novel surfactant therapies for respiratory diseases and other potential applications.
Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies.
Roivant Sciences
Roivant Sciences is a biopharmaceutical company focused on the development of medicines and healthcare technologies to patients.
Tonix Pharmaceuticals
Tonix Pharmaceuticals develops pharmaceutical products for central nervous system disorders.
Viking Therapeutics
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Virta Health
Virta delivers a clinically-proven treatment to reverse type 2 diabetes and other chronic metabolic diseases.
Current Advisors List
Board_member
Current Employees Featured
Cedric Francois Co-founder, Chief Executive Officer , and President @ Apellis Pharmaceuticals
Co-founder, Chief Executive Officer , and President
2010-01-01
Pascal Deschatelets Founder & Chief Operating Officer @ Apellis Pharmaceuticals
Founder & Chief Operating Officer
Lukas Scheibler Chief Innovation Officer @ Apellis Pharmaceuticals
Chief Innovation Officer
Nur Nicholson Chief Technical Operations Officer @ Apellis Pharmaceuticals
Chief Technical Operations Officer
Timothy Sullivan CFO @ Apellis Pharmaceuticals
CFO
Adam Townsend COO @ Apellis Pharmaceuticals
COO
2024-01-01
David O. Watson General Counsel @ Apellis Pharmaceuticals
General Counsel
2014-01-01
Mike Yeadon Consultant Acting Chief Scientific Officer @ Apellis Pharmaceuticals
Consultant Acting Chief Scientific Officer
Caroline Baumal CMO @ Apellis Pharmaceuticals
CMO
2023-01-01
Philip J. Ferrone Chief Medical Retina Advisor @ Apellis Pharmaceuticals
Chief Medical Retina Advisor
2024-03-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2014-11-20 | Potentia Pharmaceuticals | Potentia Pharmaceuticals acquired by Apellis Pharmaceuticals | N/A |
Investors List
Sixth Street
Sixth Street investment in Post-IPO Debt - Apellis Pharmaceuticals
Solasta Ventures
Solasta Ventures investment in Post-IPO Equity - Apellis Pharmaceuticals
venBio Partners
venBio Partners investment in Series E - Apellis Pharmaceuticals
Epidarex Capital
Epidarex Capital investment in Series E - Apellis Pharmaceuticals
Morningside Venture Investments
Morningside Venture Investments investment in Series E - Apellis Pharmaceuticals
Clough Capital Partners
Clough Capital Partners investment in Series E - Apellis Pharmaceuticals
Sofinnova Investments
Sofinnova Investments investment in Series E - Apellis Pharmaceuticals
Sectoral Asset Management
Sectoral Asset Management investment in Series E - Apellis Pharmaceuticals
F-Prime Capital
F-Prime Capital investment in Series E - Apellis Pharmaceuticals
Vivo Capital
Vivo Capital investment in Series E - Apellis Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2024-03-11 | Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor |
| 2024-01-22 | Apellis Pharmaceuticals appoints COO |
| 2023-01-05 | Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer |
Official Site Inspections
http://www.apellis.com Semrush global rank: 1.63 M Semrush visits lastest month: 14.34 K
- Host name: ec2-3-141-146-16.us-east-2.compute.amazonaws.com
- IP address: 3.141.146.16
- Location: Columbus United States
- Latitude: 39.9653
- Longitude: -83.0235
- Metro Code: 535
- Timezone: America/New_York
- Postal: 43215
More informations about "Apellis Pharmaceuticals"
Corporate Giving - Apellis CA
At Apellis, our commitment to developing transformative complement therapies extends beyond discovery and development to fully encompass our vision of being a compassionate …See details»
About Apellis - Advancing Treatment by Inhibiting the …
At Apellis, we combine courageous science and compassion to develop life-changing medicines for some of the most challenging diseases patients face. We Advance Courageous Science …See details»
Corporate Giving - Apellis
At Apellis, our commitment to developing transformative complement therapies extends beyond discovery and development to fully encompass our vision of being a compassionate …See details»
Corporate Funding - Apellis
Apellis may consider providing support for the following types of Corporate Funding. Donation. A donation is a charitable contribution to a 501(c)(3), not-for-profit organization. The donation is …See details»
Apellis Pharmaceuticals - Crunchbase Company Profile …
Apellis Pharmaceuticals is an early-stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such …See details»
Apellis Highlights Commercial Growth and Strategic Priorities at …
3 days ago Adam Townsend, chief operating officer, has decided to pursue a new opportunity as a chief executive officer at a private biotechnology company and will depart Apellis on …See details»
About Us - Apellis CA
Apellis Canada. You are now leaving Apellis.ca and being directed to an Apellis site intended for audiences in a different geography. If you continue, the information you are about to access …See details»
Apellis Medical Hub Canada
At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, a part of the body’s immune system. Our work is rooted centrally at C 3 , which is the …See details»
Apellis Pharmaceuticals - Funding, Financials, Valuation & Investors
Apellis Pharmaceuticals is registered under the ticker NASDAQ:APLS . Their stock opened with $14.00 in its Nov 9, 2017 IPO. Apellis Pharmaceuticals is funded by 19 investors. Sixth Street …See details»
Apellis Company Profile | Management and Employees List
Apellis Profile and History. Established in 2009, Apellis is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of a …See details»
Grants and Giving Requirements - Apellis
The requesting organization’s mission must be aligned with Apellis’ corporate vision and values. For healthcare charitable contributions, grants, and sponsorships, the requesting …See details»
Apellis Pharmaceuticals - Contacts, Employees, Board Members, …
Organization. Apellis Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Number of Board Member and Advisor Profiles 1. Contacts …See details»
About Apellis - Advancing Treatment by Inhibiting the …
At Apellis, we combine courageous science and compassion to develop life-changing medicines for some of the most challenging diseases patients face. We Advance Courageous Science …See details»
Apellis Announces Keli Walbert to Join the Board of Directors
5 days ago Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most …See details»
Apellis Announces Keli Walbert to Join the Board of Directors
2 days ago Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most …See details»
Career Opportunities and Benefit Programs | Apellis Pharmaceuticals
Join us as we create life-changing therapies! Read about our comprehensive health insurance programs, our financial planning and protection package, including a 401k plan, stock …See details»
Apellis Pharmaceuticals Announces Inducement Grants Under …
WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today …See details»
Apellis Pharmaceuticals Reports $709 Million in Preliminary
2 days ago Apellis Pharmaceuticals reports $709 million in 2024 U.S. net product revenues, anticipates new drug submissions and organizational changes. ... Mr. Townsend led the …See details»
Apellis Pharmaceuticals, Inc. - Drug pipelines, Patents ... - Patsnap
Apellis plans to submit a supplemental new drug application to the U.S. Food and Drug Administration in early 2025. About the VALIANT study The VALIANT phase 3 study …See details»
2021 Sustainability Report - Apellis
Nov 26, 2022 At Apellis, we advance courageous science to deliver life-changing medicines across a broad range of serious diseases by controlling complement, a part of ... we work …See details»